The city announced that its Business of the Month for February 2026 is Boucherie Eden, located at 5525 Westminster. “Open Sunday to Friday, owner Yoni Dayan works hand in hand with his mother-in-law ...

Dr. Raza Bokhari, Executive Chairman & CEO will participate in panel discussions and highlight Company's AI-enabled Drug Development Strategy ...

Board director Andrew Stevens says the gap at the top end of town will never close unless executive roles can be redesigned to better suit women.

High-pay, low-effort jobs give a wide array of freelancers the chance to earn $40 or more per hour, largely working when they ...

CSL Ltd. is out-licensing its interleukin-6 (IL-6) monoclonal antibody, clazakizumab, to Eli Lilly and Co. in a deal that brings CSL $100 million in up-front fees. A CSL spokesperson told BioWorld the ...

Eli Lilly is paying $100 million upfront (PDF) for the right to develop CSL’s phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection. Australia-based CSL picked ...

CSL granted Eli Lilly certain rights for clazakizumab CSl to receive upfront payment of $100 million CSL shares up 2.1% CSL will retain exclusive rights to develop and commercialise clazakizumab for ...

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the eve of its latest earnings announcement. Paul McKenzie, Ph.D., who’s served ...

I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen Best laptop cooling pads Best flip ...

The ASX 200 closed slightly lower, and the CSL chief executive stepped down abruptly ahead of tomorrow's half-year results. Catch up on the day's events and insights from our business reporters on the ...

CSL has gotten the Memo about the value of recombinant polyclonal immunoglobulin (IgG) antibodies. The company is signing on to a collaboration and option agreement with Memo Therapeutics that could ...